Ascendis Pharma As Stock Investor Sentiment

ASND Stock  USD 136.00  0.32  0.23%   
About 56% of Ascendis Pharma's investor base is looking to short. The analysis of the overall investor sentiment regarding Ascendis Pharma AS suggests that many traders are alarmed. The current market sentiment, together with Ascendis Pharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Ascendis Pharma AS stock news signals to limit their universe of possible portfolio assets.

Panic Vs Confidence

44

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Ascendis Pharma's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Ascendis Pharma AS.

Ascendis Historical Sentiment

Although Ascendis Pharma's investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Ascendis, such as negative comments on social media and news outlets, may cause fear in the market and push Ascendis Pharma's investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Ascendis.
  

Ascendis Pharma Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Ascendis Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Ascendis Pharma AS Historical Investor Sentiment

Investor biases related to Ascendis Pharma's public news can be used to forecast risks associated with an investment in Ascendis. The trend in average sentiment can be used to explain how an investor holding Ascendis can time the market purely based on public headlines and social activities around Ascendis Pharma AS. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Ascendis Pharma's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Ascendis Pharma and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Ascendis Pharma news discussions. The higher the estimate score, the more favorable the investor's outlook on Ascendis Pharma.
over six months ago at benzinga.com         
100 Invested In This Stock 10 Years Ago Would Be Worth 6,500 Today
benzinga news
over six months ago at news.google.com         
Ascendis Pharma Expands Capital with Warrants and Shares - TipRanks
Google News at Macroaxis
over six months ago at benzinga.com         
FDA Pushes Review Date For Ascendis Pharmas Hormone Disorder Candidate By Three Months
benzinga news
over six months ago at finance.yahoo.com         
FDA Pushes Review Date For Ascendis Pharmas Hormone Disorder Candidate By Three Months
Yahoo News
over six months ago at investing.com         
Ascendis Pharma target lifted to 140 by Morgan Stanley
Investing News at Macroaxis
over six months ago at finance.yahoo.com         
Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon ...
Yahoo News
over six months ago at benzinga.com         
Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon ...
benzinga news
over six months ago at finance.yahoo.com         
FDA extends review of Ascendis Pharmas hormone disorder therapy
Yahoo News
over six months ago at finance.yahoo.com         
UPDATE 1-FDA extends review of Ascendis Pharmas hormone disorder therapy
Yahoo News
over six months ago at seekingalpha.com         
Ascendis stock falls as FDA delays TransCon PTH review
seekingalpha News
over six months ago at investing.com         
FDA extends review of Ascendis Pharmas hypoparathyroidism drug
Investing News at Macroaxis
over six months ago at benzinga.com         
Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparath...
benzinga news
over six months ago at finance.yahoo.com         
Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparath...
Yahoo News
over six months ago at investing.com         
TransCon PTH shows promise in renal function study
Investing News at Macroaxis
over six months ago at talkmarkets.com         
Masters In Trading - Saturday, May 11
news
Far too much social signal, news, headlines, and media speculation about Ascendis Pharma that are available to investors today. That information is available publicly through Ascendis media outlets and privately through word of mouth or via Ascendis internal channels. However, regardless of the origin, that massive amount of Ascendis data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Ascendis Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Ascendis Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Ascendis Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Ascendis Pharma alpha.

Ascendis Pharma Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Childrens Growth Awareness Week Why Growth Awareness Matters
09/09/2024
2
Ascendis Pharma AS Announces Proposed Public Offering of ADSs
09/18/2024
3
Novo Nordisk Q3 Preview Will 285 Million Weight Loss Bet Offset Bearish Charts
11/05/2024
4
Heres Why BioMarin Aristotle Large Cap Growth Strategy Divested From Pharmaceutical
11/07/2024
5
Ascendis Pharma Q3 2024 Earnings Preview
11/13/2024
6
Sivik Global Healthcare LLC Buys Shares of 10,000 Ascendis Pharma AS
11/14/2024
7
Citi cuts Ascendis Pharma stock target, maintains buy rating on volume growth
11/15/2024
8
Ascendis Pharmas SWOT analysis stock faces growth hurdles amid pipeline promise - Investing.com India
11/22/2024

Complementary Tools for Ascendis Stock analysis

When running Ascendis Pharma's price analysis, check to measure Ascendis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascendis Pharma is operating at the current time. Most of Ascendis Pharma's value examination focuses on studying past and present price action to predict the probability of Ascendis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascendis Pharma's price. Additionally, you may evaluate how the addition of Ascendis Pharma to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Money Managers
Screen money managers from public funds and ETFs managed around the world